Coreline Soft and Oatmeal Health Accelerate North American Business Diversification Through Entry into the US Insurance Reimbursement Market

– Advanced lung cancer early diagnosis drives joint development with US healthcare companies

– AI revenue model optimized for $1.6B annual US insurance reimbursement structure

– Strategic partnership targeting FDA approval and global expansion

Medical AI specialist Coreline Soft announced on September 1 that it has signed a joint development agreement with US-based healthcare delivery and diagnostics company Oatmeal Health to initiate the development of next-generation AI solutions for lung cancer screening.

Oatmeal Health operates a unified clinical platform that combines AI-driven patient identification, virtual diagnostics, and CPT-based reimbursement across US Federally Qualified Health Centers (FQHCs). This collaboration goes beyond simple technology partnerships, marking a significant entry into the US insurance reimbursement market while securing leading-edge technology for lung cancer malignancy prediction.

Both companies’ core objectives are to develop an integrated CADe-CADx solution that combines Coreline Soft’s nodule detection engine (AI CADe) with Oatmeal Health’s malignancy prediction algorithm (AI CADx). This solution transcends simple lung nodule detection to quantify lesion risk levels and provide AI-based triage criteria, achieving enhanced early diagnostic accuracy and streamlined treatment decision-making.

The product targets the US low-dose chest CT lung cancer screening market and Federally Qualified Health Centers (FQHCs), enabling insurance claims through CMS’s newly established CPT codes (0721T•0722T). The solution secures a predictable, recurring revenue model by embedding a structure where screening results translate directly into actual insurance reimbursements beyond research or technical validation.

The US has approximately 14 million eligible lung cancer screening candidates, with only 2.5 million (18%) receiving annual screenings. Based on $650 per scan insurance reimbursement, this represents an annual $1.6 billion market. When expanded to include incidental finding scans, the potential market reaches 93 million cases annually.

Kim Jin-kook, CEO of Coreline Soft, emphasized: “Our collaboration with Oatmeal Health extends beyond technology partnerships to secure insurance reimbursement-based revenue structures for actual US patients and establish leading technology in the lung cancer screening market. This demonstrates how AI diagnostic technology evolution can drive screening reimbursement structures, improved healthcare accessibility, and revenue model innovation.”

Oatmeal Health operates US public screening programs and remote reading networks, and is one of 16 innovative startups selected for the first Accelerator cohort of CancerX, established in 2024 under the White House Cancer Moonshot Initiative. The company has been recognized for its distinctive model supporting underserved communities through digital health-based lung cancer early screening platforms.

“This partnership allows us to deliver a fully integrated, reimbursable AI diagnostic solution,” said Jonathan Govette, CEO of Oatmeal Health. “By working across Community Health Centers and health systems, we’re bridging the full continuum of care, from patient identification to diagnosis, with scalable infrastructure that meets real clinical and operational demands nationwide.”

“Coreline Soft’s aView LCS product offers excellent pulmonary nodule detection and characterization, and Oatmeal Health’s LungAI platform achieves state-of-the-art malignancy prediction accuracy. Through this collaboration, we are excited to bring to market a truly best-in-class CADe-CADx product,” said Yuri Ahuja, MD, PhD, CTO of Oatmeal Health.

Jang Yi-sik, Strategic Affairs Director at Coreline Soft, explained: “Coreline’s AI goes beyond simple reading assistance, supporting healthcare providers in conducting reliable and efficient screenings based on clinically validated technology and commercialization experience. This aligns with Oatmeal Health’s vision of expanding healthcare equity through insurance reimbursement structures and public health programs.”

Coreline Soft possesses technology validated in European and Asian national-level lung cancer screening projects. It has built a distinctive portfolio through AVIEW LCS Plus, enabling simultaneous analysis of lung cancer, emphysema, and coronary artery disease. The company has secured hospital-centered business achievements in the North American market through collaborations with Temple Health, Baylor College of Medicine, and 3DR Labs. Through this agreement, Coreline plans to expand its strategy to new partner segments, including insurance companies and platform enterprises.

저작권자 © Korea IT Times 무단전재 및 재배포 금지